Malaria caused by the Plasmodium vivax parasite is a major global health burden. Immunity
against blood-stage infection reduces parasitemia and disease severity. Duffy-binding …

Malaria is a global infectious disease that remains a leading cause of morbidity and mortality
in the developing world. Multiple environmental and host and parasite factors govern the …

Summary Pfs230 domain 1 (Pfs230D1) is an advanced malaria transmission-blocking
vaccine antigen demonstrating high functional activity in clinical trials. However, the …

Malaria transmission-blocking vaccines (TBVs) aim to induce antibodies that interrupt
malaria parasite development in the mosquito, thereby blocking onward transmission, and …

Pfs230 is essential for Plasmodium falciparum transmission to mosquitoes and is the protein
targeted by the most advanced malaria-transmission-blocking vaccine candidate. Prior …

A malaria vaccine that blocks parasite transmission from human to mosquito would be a
powerful method of disrupting the parasite lifecycle and reducing the incidence of disease in …

Pfs25 is a leading antigen for a malaria transmission-blocking vaccine and shows moderate
transmission-blocking activity and induction of rapidly decreasing antibody titers in clinical …

Malaria remains one of the biggest health problems in the world. While significant reductions
in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend …

Malaria killed over 600,000 people in 2022, a death toll that has not improved since 2015.
Additionally, parasites and mosquitoes resistant to existing interventions are spreading …

The global pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), has led to efforts in developing effective vaccine approaches. Currently, approved …